This study is evaluating whether an investigational treatment may help people with MASH (formerly NASH) who have stage F2 or F3 liver fibrosis. The goal is to determine if the treatment can improve liver health and slow disease progression.
Eligibility:
• Ages 18+
• Diagnosed with MASH and fibrosis stage F2–F3 confirmed by biopsy (recent or within 6 months)